Alimera Sciences Inc (NASDAQ:ALIM) Shifting Institutional Investors Sentiment

Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Sentiment for Alimera Sciences Inc (NASDAQ:ALIM)

Alimera Sciences Inc (NASDAQ:ALIM) institutional sentiment decreased to 0.93 in 2018 Q2. Its down -0.57, from 1.5 in 2018Q1. The ratio is negative, as 14 institutional investors opened new or increased positions, while 15 sold and decreased holdings in Alimera Sciences Inc. The institutional investors in our partner’s database now possess: 29.19 million shares, up from 28.53 million shares in 2018Q1. Also, the number of institutional investors holding Alimera Sciences Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 8 Increased: 6 New Position: 8.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $68.68 million. It focuses on diseases affecting the back of the eye or retina. It has a 6.32 P/E ratio. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

The stock decreased 1.51% or $0.015 during the last trading session, reaching $0.98. About 21,333 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 21.99% since December 8, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Analysts await Alimera Sciences, Inc. (NASDAQ:ALIM) to report earnings on February, 27. They expect $-0.06 earnings per share, up 40.00 % or $0.04 from last year’s $-0.1 per share. After $-0.05 actual earnings per share reported by Alimera Sciences, Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Armistice Capital Llc holds 0.44% of its portfolio in Alimera Sciences, Inc. for 6.94 million shares. Jw Asset Management Llc owns 413,300 shares or 0.26% of their US portfolio. Moreover, Venbio Select Advisor Llc has 0.24% invested in the company for 6.24 million shares. The California-based Acuta Capital Partners Llc has invested 0.17% in the stock. Knott David M, a New York-based fund reported 265,000 shares.

Alimera Sciences, Inc. (NASDAQ:ALIM) Ratings Coverage

Ratings analysis reveals 100% of Alimera’s analysts are positive. Out of 2 Wall Street analysts rating Alimera, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.5000 while the high is $2.75. The stock’s average target of $2.63 is 168.37% above today’s ($0.98) share price. ALIM was included in 3 notes of analysts from June 12, 2018. The firm has “Buy” rating given on Tuesday, November 27 by H.C. Wainwright. H.C. Wainwright maintained Alimera Sciences, Inc. (NASDAQ:ALIM) on Tuesday, June 12 with “Buy” rating.

More notable recent Alimera Sciences, Inc. (NASDAQ:ALIM) news were published by: Seekingalpha.com which released: “Alimera Sciences’ (ALIM) CEO Dan Myers on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” on May 06, 2018, also Prnewswire.com with their article: “Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society’s Annual Meeting – PR Newswire” published on September 13, 2018, Nasdaq.com published: “EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq – Nasdaq” on October 17, 2018. More interesting news about Alimera Sciences, Inc. (NASDAQ:ALIM) were released by: Nasdaq.com and their article: “Earnings Season Shows Strong Revenue Momentum – Nasdaq” published on July 27, 2018 as well as Prnewswire.com‘s news article titled: “Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain – PR Newswire” with publication date: May 31, 2018.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.